VRCA — Verrica Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $68.27m
- $81.57m
- $5.12m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 12 | 9.03 | 5.12 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 8.31 | 4.38 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 30.1 | 40.2 | 42.9 | 31.8 | 70.9 |
Operating Profit | -30.1 | -40.2 | -30.9 | -22.7 | -65.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -28.2 | -42.7 | -35.1 | -24.5 | -67 |
Provision for Income Taxes | |||||
Net Income After Taxes | -28.2 | -42.7 | -35.1 | -24.5 | -67 |
Net Income Before Extraordinary Items | |||||
Net Income | -28.2 | -42.7 | -35.1 | -24.5 | -67 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.2 | -42.7 | -35.1 | -24.5 | -67 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.13 | -1.71 | -1.3 | -0.675 | -1.42 |